Tunanin cewa umarnin alluran rigakafi da matakan da suka danganci tilasta yin rigakafin sune sakamakon tasirin "Big Pharma" akan gwamnatoci ya zama ruwan dare tsakanin masu sukar irin wadannan matakan. Haka kuma, tare da rigakafin Pfizer yana tafiya daga wannan nasara ta tsari zuwa wani kuma yana ƙara mamaye kasuwar rigakafin Covid-19 a duka Amurka da nahiyar Turai (ba tare da ambaton Isra'ila ba, wanda yaƙin neman rigakafinta ya ƙunshi kusan Pfizer kawai), a bayyane yake cewa ainihin abin da ake nufi a yau ta "Big Pharma" dole ne Pfizer da Pfizer kadai.
Bayan mummunan ɗaukar hoto na mummunan sakamako (musamman, thrombosis) kuma, a wasu lokuta, sa baki na tsari a ɓangaren hukumomin sa ido na ƙasa, duka biyun sauran ainihin "Big Pharma" madadin, AstraZeneca a cikin EU da Johnson & Johnson a cikin EU da Amurka, an sake komawa zuwa matsayin 'yan wasa kaɗan a waje da Burtaniya.
Zai bayyana cewa a cikin Yamma aƙalla, muna matsawa zuwa ƙaƙƙarfan ƙaƙƙarfan maganin rigakafin Covid-19 na Pfizer. Hatta maganin rigakafin Covid na Moderna - kamfani wanda ya shahara bai taba kawo magani a kasuwa a baya ba don haka wanda ba za a iya kwatanta shi da "Big Pharma" - yana kara fuskantar bincike don haifar da myocarditis a cikin samari maza kuma ana iyakance amfani da shi ga mutane sama da 30 a cikin gaba daya jerin kasashen Turai.
Pfizer, da bambanci, ya kasance ba a taɓa shi ba. Wannan ko da yake myocarditis labari ne da yawa kuma an yarda da mummunan tasirin duka allurar mRNA, Moderna. da Pfizer, kodayake Binciken kididdiga na kwanan nan ta CDC, a kowane hali, ba a sami "bambanci mai mahimmanci" a cikin rahoton myocarditis tsakanin alluran rigakafi guda biyu na maza 18-25, kuma ko da yake akwai shaida cewa Moderna yana ba da kariya mai dorewa (tasirin maganin har ma ya zama sau biyu na Pfizer watanni shida, bisa ga bayanin). wannan binciken kwanan nan [p. 11]).
Wane tabbaci mafi girma na rashin ƙarfi na "Big Pharma" - watau Pfizer - zai iya kasancewa? Amma idan Pfizer bai yi mulkin duniya shekaru biyu da suka wuce ba, ta yaya aka samu mulkin duniya a yau?
Bugu da ƙari, kamar yadda yawancin Amirkawa za su iya ganowa ne kawai lokacin da FDA ta cika amincewa da maganin "Pfizer" ba a ba Pfizer ba, bayan haka, amma ku BioNTech Masana'antar GmbH na Mainz, Jamus, ainihin mai haɓaka abin da ake kira allurar "Pfizer" daidai abokin tarayya na Pfizer ne BioNTech.
Wannan ya riga ya bayyana daga lambar sunan maganin: BNT162b2. Ba lallai ba ne a faɗi, "BNT" baya tsayawa ga Pfizer. Yarjejeniyar haɗin gwiwa tsakanin kamfanonin biyu ita ma ta bayyana a sarari cewa BNT162b2 rigakafin BioNTech ne. Don haka, baya ga abin da ya samu kai tsaye daga siyar da maganin, BioNTech yana karɓar "kuɗin kuɗin sarauta har zuwa lambobi biyu" daga Pfizer akan siyar da maganin rigakafin a yankunan da Pfizer ya keɓe.
Wannan ƙari ne ga "$ 120 miliyan a gaba, daidaito da biyan kuɗi na bincike na kusa da kuma ƙarin dala miliyan 305 a cikin yuwuwar haɓakawa, ka'idoji da biyan kuɗi na kasuwanci". (Duba sanarwar manema labarai na BioNTech nan.) BioNTech, ba zato ba tsammani, yana da Irin wannan yarjejeniya da Fosun Pharma don tallata rigakafinta a China.
Yanzu, nesa da zama "Babban Pharma," kafin barkewar cutar ta Covid-19, BioNTech ya kasance, a zahiri, ƙaramin fara gwagwarmaya, wanda, kamar Moderna, har yanzu bai kawo samfur zuwa kasuwa ba. BioNTech na kansa 2019 rahoton shekara-shekara zuwa SEC ya bayyana kamfanin kamar haka: "Mu kamfani ne na asibiti-matakin likitanci ba tare da samfuran magunguna da aka amince da siyar da kasuwanci ba."
An ci gaba da shigar da karar a zahiri, "Mun tafka asara mai yawa tun farkon mu kuma muna tsammanin za mu ci gaba da yin asara mai yawa nan gaba..." Don haka, a cikin 2nd kwata na 2020, BioNTech yana da Yuro miliyan 41.8 kawai a cikin kudaden shiga (ba samfura) da asarar fiye da sau biyu na adadin (Yuro miliyan 88.3). Godiya ga rigakafinta na Covid-19, duk da haka, bayan shekara guda, a cikin 2nd kwata na 2021, kudaden shiga ya tashi zuwa 5.31 biliyan Yuro - haɓaka fiye da ninki 100! – wanda sama da kashi uku cikin hudu (4 biliyan euro) ke samun riba.
A matsayin masanin tattalin arziki Carsten Brzeski na bankin Dutch ING sanya shi ga Reuters, BioNTech ya tafi "daga 0 zuwa 100 a cikin shekara guda kawai." BioNTech ya sanar kwanan nan Sakamakon kwata na uku nuna kiyasin kudaden shiga na sama da haka 6 Yuro biliyan da ribar da aka samu na kusan Yuro biliyan 4.7.
Labarin yadda BioNTech ya tashi daga sifili zuwa gwarzo, labari ne mai tsafta na shiga tsakani da tallafin gwamnati. Hakika, gwamnatin Jamus ta goyi bayan kafa BioNTech. Don haka ne a gaskiya gwamnatin Jamus ta bayyana fasahar kere-kere a matsayin muhimmin bangaren ci gaba, kuma, a cikin 2005, ta ƙaddamar da wani shiri na ba da tallafi wanda ainihin manufarsa ita ce haɓaka haɓaka fasahar kere kere bisa ga binciken ilimi: Farkowar fasahar kere-kere ta munana - kusan, "Biotechnology Start-Up Offensive" - ko "Go-Bio" a takaice.
Manufar, kamar yadda aka bayyana nan (mahaɗi a cikin Jamusanci), shine bayar da tallafi har zuwa zagaye biyu: kyauta ta farko ga ƙungiyar bincike tare da kyakkyawan aiki na kasuwanci sannan, tsammanin ƙungiyar bincike ta sami nasarar kafa kamfani bisa bincikenta, kyauta na biyu ga farawa.
BioNTech yana ɗaya daga cikin kamfanonin da za a kafa a ƙarƙashin tsarin shirin Go-Bio. A cikin 2007, Go-Bio ya fara ba da gudummawar Yuro miliyan 1.2 na Yuro miliyan 1.2 don tallafawa binciken wanda ya kafa BioNTech Ugur Sahin a Jami'ar Mainz game da haɓaka magungunan ciwon daji na mRNA, sannan ya biyo baya tare da kusan Yuro miliyan 3 "Go-Bio Phase II" kyauta ga sabon tushen tushen Pharma. 2010. (Don ƙarin bayani, a cikin Jamusanci, duba nan.)
A cikin shekaru masu zuwa, BioNTech zai ci gaba da jin daɗin goyon bayan jama'a: duka biyun daga gwamnatin jihar Rhineland-Palatinate, wanda Mainz babban birnin kasar ne, kuma a matsayinsa na jagora a wani abin da ake kira "cluster" na kamfanoni da cibiyoyin bincike a yankin Mainz wanda daga 2012 zuwa 2017 ya samu. Yuro miliyan 40 a tallafi (link in German) daga Ma'aikatar Ilimi da Bincike ta Tarayyar Jamus. Ana kiran gungu da sunan Tari don Tsangwama na Kariya ɗaya ko "Ci3". Kujerun Ci3 su ne matar Sahin da Babban Jami'in Kiwon Lafiya na BioNTech, Özlem Türeci, da kuma wanda ya kafa BioNTech Christoph Huber.
Amma kwararar manna na jama'a zuwa BioNTech sannan ya karu sosai a shekarar da ta gabata, lokacin da barkewar cutar sankarau ta ba kamfanin damar yin tasiri daga kokarin da ya yi na ci gaba da bunkasar cututtukan daji na mRNA don bunkasa rigakafin mRNA kan Covid-19.
da wannan lokacin Kamfanin dillancin labaran SWR na kasar Jamus ya wallafa, BioNTech ya riga ya tuntubi hukumar kula da al'amuran al'umma ta Jamus, Cibiyar Paul Ehrlich, game da shirinta na samar da rigakafin Covid-19 a Fabrairu 2020 - a daidai lokacin da rahotanni suka bazu game da cututtukan gida na Covid-19 sun fara bullowa a Turai kuma kafin WHO ta ayyana akwai annoba!
Zuwa Afrilu, an riga an fara gwajin asibiti! (Duba Rajista na Gwajin Asibiti na EU nan.) A ranar 15 ga Satumba, gwamnatin Jamus ta ba da sanarwar cewa tana samar da BioNTech Yuro miliyan 375 a cikin tallafi (mahaɗi a cikin Jamusanci) don tallafawa rigakafinta na Covid-19. Bankin Turai na zuba jari ya riga ya shiga Yuro miliyan 100 na tallafin bashi. Ba dole ba ne a biya kuɗin tallafin Jamus.
Amma tare da matsakaicin matsakaicin kuɗin haraji na kamfanoni na kusan kashi 30% a cikin Jamus da ingantaccen ƙimar tarayya kusan kashi 16%, gwamnatin Jamus ta yi kiyasin samun kyakkyawar dawowa kan jarin ta. Bisa lafazin hasashen kamfanin a halin yanzuAna sa ran BioNTech zai sami Yuro biliyan 16-17 a cikin kudaden shigan rigakafin Covid-19 na 2021.
Tuni bayan sanarwar sakamakon kwata na biyu na BioNTech, masanin tattalin arzikin Jamus Sebastian Dullien lissafta Cewa kudaden shiga na BioNTech kadai zai wakilci kusan kashi 0.5% na GDP na Jamus kuma don haka ke samar da ci gaban 0.5% a cikin GDP na Jamus - watau tun da BioNTech bai ba da gudummawa da gaske ba ga GDP na Jamus a baya! Ta haka ne BioNTech kadai zai yi lissafin kusan kashi 1/8 na ci gaban GDPn Jamus na shekarar 2021.
Waɗannan ƙididdiga sun dogara, duk da haka, akan hasashen samun kuɗi kaɗan kaɗan da haɓakar haɓakar GDP sosai. Dangane da hasashen halin yanzu na ci gaban 2.4% na Jamus, BioNTech kadai zai yi lissafi fiye da 1/5 na ci gaban Jamus. A cewarta mafi kwanan nan saki kudi, haka kuma, lissafin harajin kamfanin na 2021 zuwa yau ya zo sama da Yuro biliyan 3.
Shugabar Hukumar Tarayyar Turai Ursula von der Leyen ta ba da lambar yabo ta Kasuwancin Kasuwanci na Majalisar Atlantika ga Shugaban Pfizer da Shugaba Albert Bourla a ranar 10 ga Nuwamba, 2021.
Ga duk maganar ikon Big Pharma, rigakafin Covid-19 wanda a halin yanzu ya zama ma'auni a duk faɗin yammacin duniya yana da mafi ƙarfin tallafi na jihohi kuma mai ɗaukar nauyin jihar shine Jamus. Wannan ya tayar da batutuwa masu ban tsoro musamman ga Tarayyar Turai, inda kwangilar allurar rigakafin ga dukkan kasashe membobi 27 aka yi shawarwari daga Hukumar Tarayyar Turai wacce tsohuwar ministar tsaron Jamus Ursula von der Leyen ke jagoranta.
(Kwamitin ya sami taimakon “Tawagar Haɗin Kan Tattaunawa” da ke wakiltar ƙasashe membobi bakwai ciki har da Jamus [duba ƙarƙashin “tattaunawar rigakafin” nan]; wanda ke nufin cewa Jamus a zahiri tana shiga tattaunawa tare da mai kare kanta. Wataƙila ba abin mamaki ba ne, an ba da umarnin mafi girman adadin allurai daga wanin BioNTech/Pfizer [duba ƙarƙashin “Mene ne sakamakon…” nan.)
Amma tare da Jamus ta iya haɓaka ƙarfinta da aiwatar da ita a kan sikelin duniya daidai ta hanyar Tarayyar Turai, tallafin Jamus na rigakafin BioNTech / "Pfizer" shi ma ya tayar da batutuwa ga duniya gaba ɗaya.
[gyara: Labarin da ke sama yayi kuskuren buga sanarwar manema labarai na 2018 BioNTech akan yarjejeniyar haɗin gwiwa ta pre-Covid BioNTech-Pfizer lokacin da ake tattaunawa akan biyan kuɗin sarauta na Pfizer (da sauran) zuwa BioNTech. A ƙarƙashin sharuɗɗan rigakafin BioNTech-Pfizer Covid-19 hadin gwiwa, BioNTech ba ya karɓar "har zuwa lambobi biyu na biyan kuɗin sarauta" daga Pfizer akan tallace-tallacen rigakafin, amma a maimakon haka cikakken kashi 50% na ribar Pfizer akan irin wannan tallace-tallace. Don ƙarin bayani, duba labarina na kwanan nan "50-50 Raba: BioNTech da Pfizer Illusion." Bugu da kari, labarin ya lissafta yuwuwar gudummawar BioNTech ga ci gaban Jamus a shekarar 2021 bisa kiyasin Sebastien Dullien da sake fasalin kudaden shiga da hasashen ci gaban. A ƙarshe, Yuro biliyan 19 na BioNTech a cikin kudaden shiga na 2021 zai kai kusan kashi 10% na ci gaban Jamus.]
-
Robert Kogon shi ne sunan alkalami na wani ɗan jarida da ake bugawa da yawa wanda ke yin rubuce-rubuce kan al'amuran Turai.
Duba dukkan posts
